Novo Nordisk’s Wegovy and copyright, each driven by semaglutide, have revolutionized being overweight procedure by way of unparalleled weight loss outcomes.This led Novo Nordisk to conduct more investigate into larger dosages of semaglutide especially for weight management.By 2022 the popularity of Novo's Wegovy and copyright for weight loss was